Home > Publications database > The impact of tumor microenvironment and treatment schedule on the effectiveness of radiation therapy. > print

001     304600
005     20250919115036.0
024 7 _ |a 10.1371/journal.pone.0331509
|2 doi
024 7 _ |a pmid:40961159
|2 pmid
037 _ _ |a DKFZ-2025-01919
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Dimou, Kyprianos
|0 0009-0000-4951-0499
|b 0
245 _ _ |a The impact of tumor microenvironment and treatment schedule on the effectiveness of radiation therapy.
260 _ _ |a San Francisco, California, US
|c 2025
|b PLOS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1758201488_22393
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a External Beam Radiation Therapy (EBRT) is predominantly administered using Conventionally Fractionated Radiotherapy (CFRT), that is 2 Gy per fraction. However, Moderately Hypofractionated Radiotherapy (MHRT) (approx. 2.5-3 Gy per fraction) and Stereotactic Body Radiotherapy (SBRT) (approx. 6-24 Gy per fraction) regimen are currently clinically investigated or even recently included in standard clinical practice. In addition, hyperfractionated radiotherapy (<1.8-2 Gy per fraction) is also clinically investigated or already used in standard clinical practices. The therapeutic effects of each of these radiotherapy schedules might depend on the degree of radioresistance of the tumor but also on properties of the tumor microenvironment, such as tumor perfusion and oxygenation. Here, building on previous work, we developed a mathematical model to investigate optimal radiotherapy treatment protocols in solid tumors. The model incorporates direct effects of radiation on cancer cells and accounts for the impact of tumor perfusion and oxygenation on the efficacy of radiation therapy. The model was able to accurately reproduce both preclinical and clinical data from different radiotherapy treatment schedules. It confirmed that greater tumor perfusion and thus, oxygenation improves treatment effectiveness by increasing the number of cancer cells killed during the treatment period. It further predicted that this effect is more pronounced for radioresistant tumors, meaning that changes in tumor perfusion of more radioresistant tumors have a greater impact on the percentage of surviving cells at the end of the treatment. The mathematical model provides mechanistic insights into the effectiveness of various radiotherapy schedules and guidelines for how modifying the tumor microenvironment to restore perfusion can affect radiation therapy.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 2 |a Tumor Microenvironment: radiation effects
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neoplasms: radiotherapy
|2 MeSH
650 _ 2 |a Neoplasms: pathology
|2 MeSH
650 _ 2 |a Neoplasms: blood supply
|2 MeSH
650 _ 2 |a Dose Fractionation, Radiation
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Models, Biological
|2 MeSH
650 _ 2 |a Models, Theoretical
|2 MeSH
700 1 _ |a Roussakis, Yiannis
|0 0000-0002-9367-4906
|b 1
700 1 _ |a Zamboglou, Constantinos
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Stylianopoulos, Triantafyllos
|b 3
773 _ _ |a 10.1371/journal.pone.0331509
|g Vol. 20, no. 9, p. e0331509 -
|0 PERI:(DE-600)2267670-3
|n 9
|p e0331509
|t PLOS ONE
|v 20
|y 2025
|x 1932-6203
909 C O |o oai:inrepo02.dkfz.de:304600
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PLOS ONE : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-02-08T09:37:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-02-08T09:37:46Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-02-08T09:37:46Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-02-08T09:37:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-16
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-16
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-16
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK Koordinierungsstelle Freiburg
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21